Ranolazine

"Ranolazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.

Descriptor ID	D000069458
MeSH Number(s)	D02.065.199.092.850 D02.092.146.113.092.850 D03.383.606.841
Concept/Terms	Ranolazine Ranolazine N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide Renolazine Ranolazine Hydrochloride Ranolazine Hydrochloride Hydrochloride, Ranolazine Ranolazine Dihydrochloride Dihydrochloride, Ranolazine Ranolazine HCl HCl, Ranolazine Ranexa Ranexa RS 43285-193 RS 43285-193 RS 43285 193 RS 43285193 RS 43285 RS 43285 43285, RS RS-43285 RS43285

Below are MeSH descriptors whose meaning is more general than "Ranolazine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Anilides [D02.065.199]
Acetanilides [D02.065.199.092]
Ranolazine [D02.065.199.092.850]
Amines [D02.092]
Aniline Compounds [D02.092.146]
Anilides [D02.092.146.113]
Acetanilides [D02.092.146.113.092]
Ranolazine [D02.092.146.113.092.850]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperazines [D03.383.606]
Ranolazine [D03.383.606.841]

Below are MeSH descriptors whose meaning is more specific than "Ranolazine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ranolazine" by people in this website by year, and whether "Ranolazine" was a major or minor topic of these publications.

Bar chart showing 24 publications over 13 distinct years, with a maximum of 5 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	2	2
2007	0	2	2
2008	0	2	2
2009	0	1	1
2010	0	3	3
2011	0	5	5
2012	0	2	2
2014	0	1	1
2015	1	0	1
2016	1	0	1
2017	1	1	2
2018	1	0	1
2019	1	0	1

Below are the most recent publications written about "Ranolazine" by people in Profiles.

Stabenau HF, Shen C, Tereshchenko LG, Waks JW. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil. Heart Rhythm. 2020 03; 17(3):460-467.

View in: PubMed
Sicouri S, Belardinelli L, Antzelevitch C. Effect of autonomic influences to induce triggered activity in muscular sleeves extending into the coronary sinus of the canine heart and its suppression by ranolazine. J Cardiovasc Electrophysiol. 2019 02; 30(2):230-238.

View in: PubMed
Burashnikov A. Late INa Inhibition as an Antiarrhythmic Strategy. J Cardiovasc Pharmacol. 2017 Sep; 70(3):159-167.

View in: PubMed
Shah NR, Cheezum MK, Veeranna V, Horgan SJ, Taqueti VR, Murthy VL, Foster C, Hainer J, Daniels KM, Rivero J, Shah AM, Stone PH, Morrow DA, Steigner ML, Dorbala S, Blankstein R, Di Carli MF. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc. 2017 May 04; 6(5).

View in: PubMed
Gong M, Zhang Z, Fragakis N, Korantzopoulos P, Letsas KP, Li G, Yan GX, Liu T. Role of ranolazine in the prevention and treatment of atrial fibrillation: A meta-analysis of randomized clinical trials. Heart Rhythm. 2017 01; 14(1):3-11.

View in: PubMed
Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol. 2015 Oct; 8(5):1048-56.

View in: PubMed
Burashnikov A, Di Diego JM, Barajas-Mart?nez H, Hu D, Zygmunt AC, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail. 2014 Jul; 7(4):627-33.

View in: PubMed
Sicouri S, Blazek J, Belardinelli L, Antzelevitch C. Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol. 2012 Apr; 5(2):371-9.

View in: PubMed
Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol. 2012 Apr; 5(2):400-8.

View in: PubMed
Sicouri S, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm. 2012 Mar; 9(3):422-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement